Genomic analysis of families with different types of cancer
Official title: Genomic Analysis of Families With a History of Discordant Cancers
Run by Case Comprehensive Cancer Center · NCT04860453 · Data updated 2026-11-12
This study is testing whether analyzing the DNA of families with a strong history of different types of cancer can help find new gene mutations linked to those cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | November 17, 2020 |
| Main results expected | July 1, 2028 |
| Study ends | July 1, 2028 |
| Registry record updated | September 3, 2025 |
| Trial ID | NCT04860453 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with a family history of discordant cancers and those who have been diagnosed with cancer themselves.
✕Probably not a fit
Patients with known high penetrance cancer susceptibility genes or those unable to provide a blood sample will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to identify novel gene mutations linked to a family history of discordant cancers by analyzing DNA from both affected and unaffected family members. Participants will provide blood samples for whole exome sequencing (WES) to explore the genetic basis of cancer. The study will include individuals with a significant family history of cancer, focusing on those with five or more relatives diagnosed with different types of cancer. Clinical information and family medical histories will also be collected to enhance understanding of genetic factors in cancer development.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and identification of inherited cancer syndromes, potentially improving cancer prevention and treatment strategies.
How similar studies have gone: Other studies have shown success in identifying genetic mutations related to cancer, making this approach promising but still exploring novel aspects.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Affected patient with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing and consent to a multicancer panel --This cohort is meant as a real world control group receiving routine standard of care and is not eligible for WES. * Affected patient with a family history of 5 or more discordant cancers in unilateral descent within a 3-generation pedigree. * Unaffected family members within such kindreds will be eligible for WES as long as a minimum of 2 affected and 1 unaffected family members consent to WES as trial participants. Exclusion Criteria: * Unable to safely provide a blood sample for genetic testing * Unable to receive or decline to receive genetic counselling through the telephone, video conference, or in person * Families known to segregate a previously identified high penetrance cancer susceptibility gene identified through routine medical genetics evaluation are not eligible WES * Family is not amenable to routine medical genetics SOC genetics evaluation.
Where it's running
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Anna Mitchell, MD PhD — University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
- Study coordinator: Anna Mitchell, MD PhD
- Email: CTUReferral@UHhospitals.org
- Phone: 1-800-641-2422
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exploring genetic differences in twins with childhood brain tumors
This study looks at the genetic differences in identical twins who have childhood brain tumors to see how these differences might affect their cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.